BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 17576461)

  • 1. Temozolomide for the treatment of metastatic melanoma.
    Quirbt I; Verma S; Petrella T; Bak K; Charette M;
    Curr Oncol; 2007 Feb; 14(1):27-33. PubMed ID: 17576461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-agent interleukin-2 in the treatment of metastatic melanoma.
    Petrella T; Quirt I; Verma S; Haynes AE; Charette M; Bak K;
    Curr Oncol; 2007 Feb; 14(1):21-6. PubMed ID: 17576460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib in multiple myeloma and lymphoma: a systematic review and clinical practice guideline.
    Reece D; Imrie K; Stevens A; Smith CA;
    Curr Oncol; 2006 Oct; 13(5):160-72. PubMed ID: 22792013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemotherapy for the treatment of metastatic malignant melanoma: a clinical practice guideline.
    Verma S; Petrella T; Hamm C; Bak K; Charette M;
    Curr Oncol; 2008 Apr; 15(2):85-9. PubMed ID: 18454183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temozolomide for the treatment of metastatic melanoma: a systematic review.
    Quirt I; Verma S; Petrella T; Bak K; Charette M
    Oncologist; 2007 Sep; 12(9):1114-23. PubMed ID: 17914081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer.
    Jonker D; Rumble RB; Maroun J;
    Curr Oncol; 2006 Oct; 13(5):173-84. PubMed ID: 22792014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ifosfamide-based combination chemotherapy in advanced soft-tissue sarcoma: a practice guideline.
    Verma S; Younus J; Stys-Norman D; Haynes AE; Blackstein M
    Curr Oncol; 2007 Aug; 14(4):144-8. PubMed ID: 17710206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
    Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
    Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
    Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
    J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of single brain metastasis: a practice guideline.
    Mintz A; Perry J; Spithoff K; Chambers A; Laperriere N
    Curr Oncol; 2007 Aug; 14(4):131-43. PubMed ID: 17710205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alemtuzumab in chronic lymphocytic leukemia.
    Fraser G; Smith CA; Imrie K; Meyer R;
    Curr Oncol; 2007 Jun; 14(3):96-109. PubMed ID: 17593982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
    García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
    Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
    Clark JI; Moon J; Hutchins LF; Sosman JA; Kast WM; Da Silva DM; Liu PY; Thompson JA; Flaherty LE; Sondak VK
    Cancer; 2010 Jan; 116(2):424-31. PubMed ID: 19918923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of metastatic malignant melanoma.
    Atallah E; Flaherty L
    Curr Treat Options Oncol; 2005 May; 6(3):185-93. PubMed ID: 15869730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial.
    Hwu WJ; Krown SE; Panageas KS; Menell JH; Chapman PB; Livingston PO; Williams LJ; Quinn CJ; Houghton AN
    J Clin Oncol; 2002 Jun; 20(11):2610-5. PubMed ID: 12039921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
    Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
    Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
    Hwu WJ; Lis E; Menell JH; Panageas KS; Lamb LA; Merrell J; Williams LJ; Krown SE; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
    Cancer; 2005 Jun; 103(12):2590-7. PubMed ID: 15861414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group.
    Bafaloukos D; Gogas H; Georgoulias V; Briassoulis E; Fountzilas G; Samantas E; Kalofonos Ch; Skarlos D; Karabelis A; Kosmidis P
    J Clin Oncol; 2002 Jan; 20(2):420-5. PubMed ID: 11786569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
    Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
    Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.